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Sir,
Palmoplantar psoriasis is a condition characterised by erythema, infiltration, fissuring, and scaling, and is 
sometimes associated with recurrent crops of sterile pustules, occasionally presenting with hyperkeratosis. 
This chronic inflammatory skin disease can be disabling in cases where patients experience painful fissuring 
and may affect daily activities, possibly resulting in debilitating pain.1
Smoking has been observed to be a trigger in the development of this form of psoriasis through 
oxidative, inflammatory, and genetic mechanisms. Nicotine damages skin by increasing the reactive oxygen 
species and decreasing the expression of antioxidants. It also stimulates innate immune cells integral to the 
pathogenesis of psoriasis including macrophages, keratinocytes, and dendritic cells.2 A better understanding 
of palmoplantar psoriasis has disclosed some differences when compared to psoriasis vulgaris regarding age 
of onset, female predominance, and smoking influence.3 The impact of the cessation of smoking during the 
clinical course of the disease remains to be established. We present a case of refractory palmar psoriasis with 
clinical improvement after cessation of smoking.
A 51-year-old male farmer presented to the Department of Dermatology at San Cecilio University 
Hospital, Granada, Spain, with palmoplantar psoriasis. He had been suffering this condition since the age of 
34 with periods of remission and aggravation. His medical history showed that he had been a heavy smoker 
(3 packs per day) for the last 35 years. His lesions had become extremely painful and incapacitated him to 
the extent that he was unable to work. An examination revealed scaly hyperkeratotic plaques with fissures 
on both hands [Figure 1]. His nails were also dramatically affected showing distal onycholysis, subungual 
hyperkeratosis, Beau’s lines and oil spots [Figure 2]. His feet were free of lesions. Several therapies were 
used including topical steroids, psoralen and ultraviolet A (PUVA) light therapy, and methotrexate, but no 
improvement was observed. 
Psoriasis on hands and feet is a disabling condition which highly impacts quality of life (QOL). It is a 
particularly challenging form of psoriasis due to its resistance to treatment; topical therapies usually fail 
because of the thickened horny layer of epidermis in these areas, and systemic conventional therapies do 
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Figure 1: Tender scaly plaques on palmar side of the 
hands. The patient was unable to work. 
 
Figure 2: Nails were dramatically involved showing 
distal onycholysis, subungal hyperkeratosis, Beau’s lines, 
and oil spot.
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not always give a therapeutic gain. Many of these systemic therapies used in plaque psoriasis have been used 
in palmoplantar psoriasis, but none are generally accepted as being reliably effective. In addition, patients 
with this condition are excluded from most clinical trials of psoriasis, which leads to no evidence-based 
consensus regarding a therapeutic strategy for this disease. With all these considerations in mind, we also 
have to consider other environmental conditions that have an effect on the therapeutic results of smoking. 
Patients with psoriasis are more likely to develop hypertension, obesity, depression, or psychiatric disorders, 
and become drinkers or smokers due to the impact of this disease on their QOL.4,5 
Tobacco use is preventable, and has been shown to exacerbate pre-existing palmoplantar psoriasis, but 
its use has also been found among subjects with new onset of the disease.6 Moreover, smoking has been 
suggested as an aggravating factor in the treatment outcomes and is believed to drive disease severity.6,7 The 
pathogenic mechanism is uncertain but may be linked to the products of smoking which induce oxidative 
stress, encouraging inflammatory cells to accumulate in the epidermis, altering the function of these cells 
and the extracellular matrix turnover.8 Smoking enhances expression of genes known to confer an increased 
risk of psoriasis (HLA-Cw6, HLA-DQA1*0201 and CYP1A1) and initiates the formation of free radicals that 
stimulate cell-signalling pathways active in psoriasis, including mitogen-activated protein kinase, nuclear 
factor-kB, and Janus kinase/signal transducers and activators of transcription. Nicotine stimulates cells 
associated with the pathogenesis of psoriasis such as dentritic cells, macrophages, and keratinocytes. These 
cells release cytokines which activate T-lymphocytes and perpetuate a cycle of chronic inflammation.3
Improved understanding of the possible link between smoking and palmoplantar psoriasis may provide 
further insight into mechanisms underlying smoking, psoriasis, and its improvement after cessation of 
smoking. In a case series study, up to 95% of patients with psoriasis of the hands and feet were former or 
current smokers, but the impact of cessation in the clinical course of the disease has not been clarified yet.9 
In our case, a satisfactory response to methotrexate (15 mg/week) and emollients was observed only after 
cessation of smoking. Physicians should keep this in mind and carefully investigate the possibility of a patient 
being a smoker if that patient is refractory to conventional therapies. In unresponsive cases of psoriasis, 
smoking  may be responsible for the refractoriness. Discontinuation of smoking may lead to a satisfactory 
response, as was seen in our patient. 
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